Epilepsy News Around the World
News articles of interest will be linked here for a period of time. Submit news articles to .
We have received a reminder notice from GSK that retigabine (Trobalt®/Potiga®) will be removed from clinical use at the end of June. Please discuss the issues with any patient who remains on the medication and how they need to be transitioned to other drugs as clinically indicated. Details here.
Published jointly by the Indian Epilepsy Association and the Indian Epilepsy Society in 2017 and formally released during the inaugural function of the joint Annual conference of the IEA and IES at Patna on February 17, 2017.
The purpose is to make this data readily available to people with epilepsy, their caregivers, physicians, and the general public. Note that the intent is solely to make available the various provisions under the Indian Law. Users must make the final decision about their individual situation after verifying the facts in consultation with the legal experts.
The 25th anniversary of the founding of a medical journal is a notable milestone and a cause for celebration. Many journals do not survive as long. Seizure — European Journal of Epilepsy has now reached this milestone. If you would like to download a free copy of the 25th anniversary Special Issue containing over 30 fantastic review articles written by well-known international experts please visit epilepsy.org.uk/ilae
We hope that you will enjoy your read and join us in wishing Seizure — European Journal of Epilepsy all the very best for the next quarter century and beyond. Please feel free to pass this invitation to any colleagues or others who may be interested in reading the anniversary issue of Seizure
Markus Reuber, Editor-in-Chief, Seizure — European Journal of Epilepsy
NIH Awards $21 Million to Research Consortium to Study Epilepsy in Patients with Traumatic Brain Injuries
An international consortium of academic research institutions have been awarded a $21 million grant from the National Institutes of Health (NIH) to develop better ways to prevent epilepsy in patients who have suffered traumatic brain injuries.
The grant will be led by seven principal investigators at five institutions: Albert Einstein College of Medicine, David Geffen School of Medicine at UCLA, the Keck School of Medicine at the University of Southern California, University of Melbourne and University of Eastern Finland. Read more…
This report describes outcomes from the South Carolina Epilepsy Surveillance System (SCESS). The SCESS is the only statewide epilepsy surveillance system based on administrative data, coordinated by the Medical University of South Carolina and state agencies, with CDC support (FY02-FY14). SCESS estimates incidence, prevalence, mortality, and associated risk factors, access to care/specialty care, and sociodemographic characteristics, using existing statewide ICD-9-CM coded data sets (2000-2014) representing: hospitalizations, hospital ED visits, and physician office visits.
Epilepsy Alliance Europe, a not-for-profit organization established under the auspices of the ILAE and the IBE, has launched a new website, EpilepsyAllianceEurope.org.
Read more about the organization and the website in the October 2016 newsletter
1-6 May 2018
Session proposal submission deadline extended to 15 November 2016
The European Commission has just launched a public stakeholder consultation which will feed into the interim evaluation of Horizon 2020, available at http://ec.europa.eu/research/consultations/interim_h2020_2016/consultation_en.htmThis is an opportunity for members of our community to express their view on how the H2020 framework program has contributed to epilepsy research. Unlike the previous FP7 framework program where epilepsy was selectively targeted, H2020 is not disease-oriented, resulting in calls on broad topics such as chronic non communicable diseases, where epilepsy projects would have to compete with conditions such as Stroke, Alzheimer disease, Depression, Schizophrenia, Cardiovascular diseases, Diabetes or Cancer. All these conditions benefit from a much greater publication track record and research support than epilepsy, making competition within the same call extremely challenging.
Art Competition to celebrate International Epilepsy Day 2017 – Monday 13th February
This competition is open to everyone! All are encouraged to take part in this great event so that, together, we can raise awareness about epilepsy on International Epilepsy Day.
Prizes: Under 12 years: 1st place US$500; 2 runners-up of US$250 each. Over 12 years: 1st place US$500; 2 runners-up of US$250 each. In addition, all entries received will be placed in a gallery on the Epilepsy Day website | Competition rules | Entry form
Opportunity for high-level epilepsy experts to join an important EU Working Group and influence epilepsy research funding
The European Commission offers an opportunity to have a concrete influence on the direction of EU research policies by inviting those interested to apply to the High Level Group on maximizing the impact of EU Research and Innovation programmes. The group will be formed with regard to an interim evaluation of Horizon 2020 that the Commission is planning to carry out by the end of 2017. The Commission will invite a High Level Group of personalities and authoritative experts to draw strategic conclusions on maximising the impact of EU Research and Innovation programmes in the future and formulate a vision for future EU Research and Innovation.
This presents a genuine opportunity for the brain space to get actively involved in shaping not only the evaluation of Horizon 2020, but also the direction of the H2020 successor — the shape of the next EU Framework Programme will be closely related to the evaluation of H2020.
The ILAE has been informed that GlaxoSmithKline has made the decision to discontinue Trobalt/Potiga (retigabine/ezogabine) from all markets in which the product is currently still available. This decision has been reached based on the very limited usage of the medicine in patients with epilepsy and the continued decline in new patient initiation. The decision has not been driven by the identification of a new safety issue, or the conclusion that the risk/benefit of the product is no longer acceptable in its licensed indication. Trobalt/Potiga will remain available to existing epilepsy patients until the end of June 2017 to enable identification of an appropriate alternative where required, after which the license will be withdrawn. In the meantime HCPs are being advised to start transitioning their patients off the medicine. More information about discontinuation …
Epilepsy League supports innovative research project English
Prof. Jean-Marc Fritschy and Tilo Gschwind of the University of Zurich have been awarded this year‘s Research Grant of CHF 25,000 by the Swiss League Against Epilepsy. With the help of innovative optogenetics, the researchers are investigating the development of epilepsy and paving the way for new treatment methods.
Two awards open to bidding:
The Michael Prize is one of the most highly regarded international awards for the best contribution to scientific and clinical research which promote further developments in epileptology. Awarded biennially, it is specially designed to attract scientists not older than 45 years of age. Submission deadline: 31 December, 2016.
Prof. Elio Lugaresi passed away on December 22, 2015 in his 89th year. His passing leaves many in the neurologic community reflecting on his enormous legacy to the discipline. Elio Lugaresi's career was devoted to the study of neurology, neurophysiology, epilepsy, and above all sleep in all its aspects, a passion he pursued well into retirement.
Prof. Lugaresi was Ambassador for Epilepsy for the International League against Epilepsy from 1979, a corresponding member of the American Neurological Association and honorary Member of the Association for Sleep Disorders Centers, the German EEG Society, Société Française de Neurologie, Spanish League against Epilepsy, Italian Society of Sleep Medicine and the American Sleep Disorders Association.
When Hanneke de Boer died peacefully in her own home after a long illness faced with great dignity a light was extinguished on a life devoted to sufferers with epilepsy. Hanneke was one of the longest serving and greatest advocates of people with epilepsy of all ages, not only in her much loved country, The Netherlands, but across the world…
Enter the new photo competition for International Epilepsy Day 2016. The theme is "Yes, I can," to demonstrate achievement in overcoming obstacles, or achievement despite obstacles. The best photographs will form the International Epilepsy Day exhibition, taking place in the European Parliament in Strasbourg from Monday 1st to Friday 5th February 2016. All entries will also be placed in a gallery on the International Epilepsy Day website www.epilepsy.org.
Winners will receive US $1,000, and will be awarded in two categories: Photos taken with regular cameras, and photos taken with smartphones or tablets. All photos must be of high resolution; should reflect "the feeling of achievement;" and must include the hashtag #epilepsyday in some way. Read complete competition rules and guidelines.
DEADLINE FOR ENTRIES EXTENDED TO 17 January 2016
SUDEP Awareness Day was created by UK charity SUDEP Action and is dedicated to raising awareness of SUDEP all around the world. It was launched last year and was supported by 45 epilepsy organisations from around the world. SUDEP Awareness Day is celebrated annually on 23 October.
The day is aimed at:
World Stroke Day is on Thursday the 29th October 2015. The World Stroke Organization's theme for World Stroke Day 2015 is "I am Woman." The World Stroke Organization is calling on communities and individuals to use World Stroke Day to show they care. Share information about stroke prevention and ask the women in your community and your life to have a health check to avoid preventable stroke and cardiovascular disease.
This book presents a methodology for identifying and classifying lusters of risks that lead to SUDEP. Developed over the last two years, the SUDEP Classification System and Risk Factor Cluster ID method will help to address gaps in our knowledge about the causes and possible prevention of this tragic complication.
Edited by: Claire M. Lathers, Paul L. Schraeder, Jan E. Leestma, Braxton B. Wannamaker, Richard L. Verrier, Steven C Schachter, M.D.
Read older World Epilepsy News items here.